Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nolato ABFRA:NBF +0.12%80 Buyback Yield % is 0.00 as of Jul. 15, 2026. GuruFocus rates FRA:NBF with a GF Score™ of 80/100 and a GF Value™ of €4.76 (Fairly Valued). The stock has 2 warning signs investors should review. Among 347 Medical Devices & Instruments companies, Nolato AB ranks worse than 288184.15% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Nolato AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NBF vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, Nolato AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nolato AB Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nolato AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Nolato AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nolato AB (FRA:NBF) has a Buyback Yield % of 0.00 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nolato AB and its competitors. According to the industry distribution chart, Nolato AB ranks #999999 out of 347 companies in the Medical Devices & Instruments industry.
Is Nolato AB's Buyback Yield % too high?
Nolato AB's current Buyback Yield % is 0.00. Based on the distribution chart, Nolato AB ranks #999999 out of 347 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nolato AB has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nolato AB's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nolato AB ranks #999999 out of 347 companies for Buyback Yield %. This places Nolato AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nolato AB and its competitors. Nolato AB's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nolato AB stock overvalued right now?
Based on GuruFocus' analysis, Nolato AB (FRA:NBF) is currently considered Fairly Valued. The stock's GF Value™ is €4.76, compared to a current price of €4.34 — trading 8.8% below its estimated fair value. The current Buyback Yield % is 0.00. Nolato AB's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Nolato AB (FRA:NBF), the current Buyback Yield % is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nolato AB (FRA:NBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nolato AB stock appears to be undervalued.
The current stock price of €4.34 is trading 8.8% below its estimated GF Value™ of €4.76.
GuruFocus considers Nolato AB to be Fairly Valued.
Key valuation signals for FRA:NBF:
Buyback Yield %: 0.00
GF Value™: €4.76 vs. price of €4.34 (8.8% below fair value)
No single metric tells the full story. See the FRA:NBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nolato AB is a Swedish company that develops and manufactures plastic, silicone, and thermoplastic elastomer products. The firm's operations are organized into two segments: Medical Solutions and Engineered Solutions. The company generates the majority of its revenue from the Medical Solutions segment, which is engaged in the development and manufacture of complex product systems and components for medical devices, the pharmaceutical industry, and diagnostics. The Engineered Solutions design, development, industrialization, and manufacture of subsystems and ready-packaged products for a range of industries, including offerings within EMC and thermal solutions. Geographically, the firm generates key revenue from the Rest of Europe and the United States.
80GF Score
Get the complete analysis for FRA:NBF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NBF has been successfully added to your 
